SUS has first drug for mild cases of covid-19

The Ministry of Health incorporated the drug composed of the antivirals nirmatrelvir and ritonavir into the Unified Health System (SUS). This is the first drug for the treatment of patients with mild to moderate cases of covid-19 and high risk of complications to be included in the public network.

The decision was published on Friday, 6, in the Diário Geral da União and the folder has 180 days to make the drug available in the SUS.

WHO recommends covid medicines

Credit: Serhii Tychynskyi/istock SUS will have first drug for mild and moderate covid

The drug will be offered to immunocompromised adult patients or patients aged 65 years or older. The treatment can only be used in case of a positive test for covid-19 and within five days after the onset of symptoms.

According to research, the drug that mixes two antivirals helps reduce the progression of the disease to severe conditions. The drug combination between nirmatrelvir and ritonavir is administered orally.

Nirmatrelvir is an inhibitory molecule of an important SARS-CoV-2 enzyme. With this, the drug prevents the virus from multiplying.

Ritonavir inhibits the action of an enzyme that degrades nirmatrelvir. This enhances the action of the drug.

More medicines in SUS

Last month, the Ministry of Health incorporated the drug baricitinib for severe cases of covid-19. The oral drug is indicated to treat hospitalized adult patients with the disease and who require oxygen by mask or nasal catheter, or who require high flow oxygen or non-invasive ventilation.

Source link

Related Articles

Leave a Reply

Your email address will not be published.

Back to top button